Oncology

Views & Analysis

Oncology R&D: the patient insights we’re still missing, and ...

Imagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and overcrowded.

News

BMS pulls speedy Opdivo approval for liver cancer in US

Bristol-Myers Squibb has withdrawn its US marketing approval for PD-1 inhibitor Opdivo as a second-line, single-agent treatment for hepatocellular carcinoma, a common form of liver cancer,

Views & Analysis

Digital tools key to immuno-oncology’s future: report

If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down.

News

Pfizer puts up $1bn to buy into Arvinas breast cancer progra...

Pfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from its protein degrader platform, which harnesses cells' natural protein-denaturing machin

News

NICE changes its mind on rare bile duct cancer drug from Inc...

Incyte's Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, after NICE concluded it provided value for money.

Views & Analysis

Oncology and a year of COVID: lessons for the future

COVID’s impact on cancer care and oncology research has been devastating, but the pandemic has also opened up opportunities to take learnings and create long-lasting change in research, pra

Oncology R&D: the patient insights we’re still missing, and ...

BMS pulls speedy Opdivo approval for liver cancer in US

Digital tools key to immuno-oncology’s future: report

Pfizer puts up $1bn to buy into Arvinas breast cancer progra...

NICE changes its mind on rare bile duct cancer drug from Inc...

Oncology and a year of COVID: lessons for the future

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

Oncology

Editor's Picks